You're describing a chemical compound, and while I can break down its components, I don't have access to specific research data or knowledge of its applications.
Here's what we can decipher from the name:
* **1-[4,6-bis(ethylamino)-1,3,5-triazin-2-yl]-1-ethylthiourea**: This is a systematic chemical name. Let's break it down:
* **1,3,5-triazin-2-yl**: This refers to a six-membered ring structure containing three nitrogen atoms (triazine) with a specific numbering system. The 2-yl indicates a substituent attached to the second carbon atom of the ring.
* **4,6-bis(ethylamino)-**: This indicates two ethylamino groups (NHCH2CH3) attached to the fourth and sixth positions on the triazine ring.
* **1-ethylthiourea**: This is a molecule containing a thiourea functional group (NH2-C(=S)-NH2) with an ethyl group (CH3CH2-) attached to one of the nitrogen atoms. The 1- indicates this ethyl group is attached to the first nitrogen of the thiourea.
* **1-**: This indicates the thiourea group is attached to the first position of the triazine ring.
**So, the compound is a triazine derivative with two ethylamino groups and a thiourea group attached to it.**
**Importance for research:**
Without further context, it's impossible to say why this specific compound is important for research. It could be:
* **A potential drug candidate:** The structure suggests it might have biological activity, particularly due to the triazine and thiourea groups, which are found in some medications.
* **A reagent for synthesis:** It could be used as a building block for the synthesis of other compounds with desired properties.
* **A model compound:** It might be used to study the properties of triazine or thiourea derivatives.
**To find out its specific research significance, you would need to:**
* **Search for it in scientific databases:** Try searching for the name or its chemical structure in databases like PubChem, SciFinder, or Reaxys.
* **Look for related publications:** Search for research articles mentioning the compound's name or similar structures.
* **Consult with a chemist or researcher:** If you have access to experts in the field, they might be able to provide specific information about its use.
I hope this helps!
ID Source | ID |
---|---|
PubMed CID | 3660272 |
CHEMBL ID | 1365436 |
CHEBI ID | 115096 |
Synonym |
---|
OPREA1_311695 |
MLS001047416 |
1-(4,6-bis-ethylamino-[1,3,5]triazin-2-yl)-1-ethyl-thiourea |
smr000425431 |
CHEBI:115096 |
1-[4,6-bis(ethylamino)-1,3,5-triazin-2-yl]-1-ethylthiourea |
AKOS005461269 |
STK527856 |
HMS2801G15 |
CHEMBL1365436 |
Q27196940 |
327170-55-8 |
DTXSID701323501 |
Class | Description |
---|---|
diamino-1,3,5-triazine | Any member of the class of 1,3,5-triazines that consists of a 1,3,5-triazine skeleton substituted by two amino groups. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 12.5893 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 11.2202 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 24.8344 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
glucocerebrosidase | Homo sapiens (human) | Potency | 19.9526 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.7783 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 29.9349 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 20.2466 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |